Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)

Kathleen M.S.E. Reyskens1, Tarryn-Lee Fisher1, Jonathan C. Schisler2, Wendi G. O’Connor2, Arlin B. Rogers2, Monte S. Willis2, Cynthia Planesse3, Florence Boyer3, Philippe Rondeau3, Emmanuel Bourdon3, M. Faadiel Essop1*

1 Cardio-Metabolic Research Group (CMRG), Department of Physiological Sciences, Stellenbosch University, Stellenbosch 7600, South Africa, 2 McAllister Heart Institute, Department of Pathology & Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA, 3 Groupe d’Etude sur l’Inflammation Chronique et l’Obésité (GEICO), Plateforme CYROI, Université de La Réunion, Saint Denis de La Réunion, France

Abstract

Although antiretroviral treatment decreases HIV-AIDS morbidity/mortality, long-term side effects may include the onset of insulin resistance and cardiovascular diseases. However, the underlying molecular mechanisms responsible for highly active antiretroviral therapy (HAART)-induced cardio-metabolic effects are poorly understood. In light of this, we hypothesized that HIV protease inhibitor (PI) treatment (Lopinavir/Ritonavir) elevates myocardial oxidative stress and concomitantly inhibits the ubiquitin proteasome system (UPS), thereby attenuating cardiac function. Lopinavir/Ritonavir was dissolved in 1% ethanol (vehicle) and injected into mini-osmotic pumps that were surgically implanted into Wistar rats for 8 weeks vs. vehicle and sham controls. We subsequently evaluated metabolic parameters, gene/protein markers and heart function (ex vivo Langendorff perfusions). PI-treated rats exhibited increased serum LDL-cholesterol, higher tissue triglycerides (heart, liver), but no evidence of insulin resistance. In parallel, there was upregulation of hepatic gene expression, i.e. acetyl-CoA carboxylase β and 3-hydroxy-3-methylglutaryl-CoA-reductase, key regulators of fatty acid oxidation and cholesterol synthesis, respectively. PI-treated hearts displayed impaired cardiac contractile function together with attenuated UPS activity. However, there was no significant remodeling of hearts exposed to PIs, i.e. lack of ultrastructural changes, fibrosis, cardiac hypertrophic response, and oxidative stress. Western blot analysis of PI-treated hearts revealed that perturbed calcium handling may contribute to the PI-mediated contractile dysfunction. Here chronic PI administration led to elevated myocardial calcineurin, nuclear factor of activated T-cells 3 (NFAT3), connexin 43, and phosphorylated phospholamban, together with decreased calmodulin expression levels. This study demonstrates that early changes triggered by PI treatment include increased serum LDL-cholesterol levels together with attenuated cardiac function. Furthermore, PI exposure inhibits the myocardial UPS and leads to elevated calcineurin and connexin 43 expression that may be associated with the future onset of cardiac contractile dysfunction.

Introduction

The human immunodeficiency virus (HIV) has infected over 40 million individuals over the last decade, with more than 5 million residing in sub-Saharan Africa [1,2]. Although highly active antiretroviral therapy (HAART) enhances life expectancy and quality of infected individuals [3,4], there is increased emphasis on HAART-mediated metabolic derangements [5] and its potential risk for cardiovascular diseases (CVD) in the long-term. Protease inhibitors (PIs) form an integral part of HAART and side-effects include development of dyslipidemia, i.e. greater production of plasma triglycerides and lipids together with an adverse cholesterol profile [6–8]. Together such derangements elicit inflammation, stress the myocardium [9], and may potentially predict the onset of insulin resistance (IR) [10,11] and cardiac dysfunction [11]. PIs are also linked to increased risk for myocardial infarction [13] and cardiovascular abnormalities [14,15], with many changes resembling coronary artery disease [16]. It is unclear whether metabolic side effects of PIs are independently and/or causally linked with cardiovascular perturbations. Moreover, the effects of PIs per se on the heart in this context are also poorly understood. Therefore, an emerging focus is to identify key metabolic and transcriptional pathways that may mediate PI-induced cardio-metabolic pathophysiology. For example, we recently found that rats exposed to 8 weeks of PI treatment displayed cardiac dysfunction [17]. Moreover, PI-treated HIV-infected individuals exhibit elevated reactive oxygen species (ROS) production [18–20] that may trigger the activation of detrimental signaling and cell death pathways [21].

HIV-PIs may also exert unfavorable effects at the gene transcriptional level, e.g. activating sterol regulatory element binding protein (SREBP) [22], a key lipid transcriptional
modulator expressed in major metabolic tissues [23]. Upon activation, SREBP binds to sterol-regulatory-element (SRE)-containing promoter sequences in lipogenic and cholesterogenic genes (e.g. 3-hydroxy-3-methyl-glutaryl-CoA reductase (herg)) that ultimately results in the production of cholesterol (high and low density lipoproteins) and sterol components [24]. The ubiquitin-proteasome system (UPS) – responsible for removal of misfolded or damaged proteins – is also implicated in the onset of such metabolic side effects. For example, the PI Ritonavir attenuates chymotrypsin- and trypsin-like activities of the 20S UPS subunit in hepatocytes [25]. As a result, degradation of apolipoprotein B (major determinant of plasma lipid levels) was diminished thus providing a potential mechanism for PI-induced hyperlipidemia [26]. Furthermore, SREBPs are ubiquitinated and degraded by the UPS [27,28] raising the possibility that an inhibition of this system may also contribute to development of dyslipidemia in HIV-infected individuals treated with PIs. Together this may establish a pro-atherogenic profile and increase the risk for the onset of CVD.

Despite such progress, the underlying molecular mechanisms responsible for HAART-induced cardio-metabolic side effects are poorly understood, and little is known about the earliest events driving this process. Whether these molecular alterations occur as a direct result of PI treatment or through the activation of additional pathways throughout the body at a later stage remain elusive. For the current study, we therefore hypothesized that PI treatment enhances myocardial oxidative stress and concomitantly inhibits the UPS, having a knock-on effect on important downstream regulators such as gap junctions and ion channels essential in cardiac physiology. We also evaluated several non-oxidative glucose metabolic circuits i.e. the polyol pathway, hexosamine biosynthetic pathway (HBP), advanced glycation end products (AGE), and PKC activation since previous work found its activation can elicit the onset of cardio-metabolic complications [29]. Since our previous ex vivo rat heart study [17] implicated altered calcium homeostasis in PI-mediated cardiac dysfunction, we further investigated calcium signaling and mitochondrial energetic regulators in an established rat model of chronic PI drug delivery. These data may explain and suggest an association between molecular changes and depressed cardiac contractile function.

Materials and Methods

Animal model. Lopinavir/Ritonavir (KaletraTM, Abbott Laboratories, Abbott Park IL) was crushed and dissolved in a 1% ethanol (vehicle) solution at human steady-state plasma concentration (7.1±2.9 mg/mL), sterile filtered and injected into a mini-osmotic pump (Alzet, Cupertino CA). Male Wistar rats (180–220 g) received either: mock surgery (sham), vehicle-, or PI-containing pump for a total of 8 weeks (n = 8 per group) as previously described [17]. Food consumption was measured via a 220 g) received either: mock surgery (sham), vehicle-, or PI-

Histologic and metabolic measurements. After 8 weeks, harvested tissues (heart, liver, adipose, pancreas and skeletal muscle) were fixed, processed and embedded in paraffin wax whereafter sections were stained with a) hematoxylin and cosin (H & E) for general morphologic evaluation and b) Sirius red for detection of collagen deposits (fibrosis).

In an identical cohort of animals, we evaluated both serum and tissue metabolite levels following PI treatment. After 8 weeks (4–7 days before termination of treatment period) rats underwent a 12–18 h overnight fast whereafter blood was collected from the jugular vein under anesthesia (isoflurane in oxygen, 5% for induction and 3% for maintenance). Serum was separated from the collected blood and analyzed for: total and LDL cholesterol, free fatty acids (FFA) and triglyceride (TG) levels (NHLS, Tygerberg Hospital, South Africa). We also evaluated the homeostatic model of assessment for insulin resistance (HOMA-IR) – here serum insulin and glucose levels were also determined (PathCare Laboratory, Stellenbosch, South Africa). The HOMA-IR was calculated as follows: (glucose [mg/dL] x fasting insulin [µU/mL])/2.43 and the equation used in accordance with the guidelines for HOMA-IR assessment in rodents [30]. Isolated heart and liver tissues were also assessed for: total cholesterol, HDL, LDL/VLDL cholesterol (Abcam, Cambridge MA) and TG content (BioVision, Milpitas CA) according to the manufacturer’s instructions.

Real-time qPCR analysis for gene expression. Total RNA was isolated from homogenized liver and heart tissues (n = 8) using the RNeasy® Mini Kit (Qiagen, Germantown, MD) according to the manufacturer’s protocols as previously described [31,32]. First strand cDNA was made using the iScriptTM cDNA synthesis kit (BioRad, Hercules CA) using 200 & 250 ng of RNA from liver, and heart tissue, respectively, and included the Solaris synthetic RNA Spike Control (Thermo Scientific, Waltham MA) to test for reverse transcription and PCR inhibition. Samples that exhibited inhibition and were not used for qPCR analysis. We evaluated expression of the following genes: acetyl-CoA carboxylase isoforms (acacx: marker of FA synthesis; acceb: marker of FA oxidation); fatty acid synthase (fasx: marker of FA synthesis); glycero-3-phosphate acyltransferase (mitochondrial) (gpam: marker of glycerol-lipid synthesis); hydroxyl-3-methyl-glutaryl-CoA reductase (hmgcr: marker of cholesterol synthesis); LDL receptor (ldlr: marker of LDL metabolism); SREBP isoforms (srebfl/2: evaluate role of SREBP); and glutamine fructose-6-phosphate amidotransferase (gfat1: HBP marker). For all qPCR reactions, 2 µL of diluted cDNA (range ~2–5 ng of cDNA) was used in technical triplicate reactions using LightCycler® 480 Probes Master mix (Roche, Indianapolis IN) for 5’ exomuclease chemistry with primers and probes per manufacturer specifications (Primers [forward/reverse]: acxb – cccgctgaattcct/gccgctgatgact; hprt1 – gcacgtgctccatc/tgaactctgc; gpdh – actgatggctcgg/ctgccgtcctgg; gusb – cctctggtggccttacctgat/cagactcaggtgttgtcatcg; gulf1 – cccaccagcagttcagtagc; RNA – tgcaagcaccacaagggaggggtagg; gusb – ctctggtggccttacctgat/cagactcaggtgttgtcatcg; hmgcr – Rn00568620_m1, hpgs – Rn00569117_m1; gpdh – Rn01765492_m1; gusb – Rn00588290_m1; acxb – Rn00573474_m1; gulf1 – Rn00573474_m1; hmgcr – Rn00573474_m1; gpdh – Rn00569117_m1; gusb – Rn00588290_m1; hmgcr – Hs9999990_s1; acxb – Rn00537447_m1; acxb – Rn00568290_m1; fasx – Rn00569117_m1; gulf1 – Rn01765492_m1; gpam – Rn00566620_m1; hmgcr –
water (H\(_2\)O)\(^{[39]}\). Assays were carried out on about 80 enzyme to reduce hydrogen peroxide (H\(_2\)O\(_2\)) into oxygen (O\(_2\)) and

Boudina

was measured in mitochondrial preparations (prepared according to the reaction. Catalase activity was determined by measuring the absorbance decrease of H\(_2\)O\(_2\) at 240 nm. The decomposition of hydrogen peroxide is a first order reaction type following H\(_2\)O\(_2\) concentration and the rate constant \(K\) for the overall reaction is

given by:

\[ K = \frac{2.3}{\Delta t} \log \left( \frac{DO_{zero}}{DO_t} \right) \]

Each measurement was considered with 4 replicates and data are expressed as catalytic unit (U) per mg of total protein. Protein carbonylation was performed on heart tissues as described before [40].

**Determination of non-oxidative pathway activation.** Briefly, collected heart tissues were homogenized with modified ice-cold RIPA buffer, the supernatant centrifuged twice at 13, 000 g for 10 min at 4°C then stored at –80°C until further use. We employed Western blotting analysis to determine total O-GlcNAc expression as a marker for myocardial HBP activation, and methylglyoxal concentrations to assess AGE pathway activation (OxiSelect™ MG ELISA Kit; Cell Biolabs, San Diego, CA). Methylglyoxal derivatives are formed from the non-enzymatic reaction of reducing carbohydrates such as glucose and carbonyl compounds (glyceraldehyde) in the Maillard reaction – products of this reaction are called AGEs. MG levels were calculated from the standard curve and are expressed as nmol per mg protein. The PKC assay was carried out using an ELISA-based method as detailed in the kit’s instruction manual (Enzo Life Sciences, Farmingdale, NY). PKC activity was determined from the standard curve and expressed as ng/min/mL.

D-sorbitol, an intermediate of the polyol pathway was measured as an index of pathway activation. D-sorbitol levels were measured as detailed in the instructions of a commercially obtained kit (BioVision K 631-100, Mountain View, CA). We calculated the sorbitol concentration (C) of samples by using the sample amount (nmol) from the standard curve (S\(_a\)), sample volume (\(V\)) used (S\(_v\)) and the dilution factor (D); C = S\(_a\)/S\(_v\)*D. We used a modified protocol (EC 2.2.1.1) from Sigma Aldrich (St. Louis, MO) to determine transketolase activity as a marker of the non-oxidative branch of the pentose phosphate pathway (PPP). Briefly, xylulose 5-phosphate and ribulose 5-phosphate are converted by transketolase in the presence of magnesium ions and thiamine pyrophosphate to glyceraldehyde 3-phosphate and sedoheptulose 7-phosphate. G 3-P is then further converted by triosephosphate isomerase to dihydroxyacetone phosphate, and with the addition of \(\beta\)-NADH and \(\alpha\)-glycerophosphate dehydrogenase to produce \(\alpha\)-glycerol phosphate and \(\beta\)-NAD to be measured spectrophotometrically at 340 nm. This protocol was adapted from de la Haba et al. ([55]) [41].

**Statistical analyses.** Data are presented as mean ± SEM, and values considered significant when \(p<0.05\). Statistical analysis was performed by one-way ANOVA, with the exception of heart function (two-way ANOVA). The Bonferroni post-hoc test comparing all groups to each other were used to determine differences (GraphPad Prism v5, San Diego, CA).

**Results**

Fasting serum levels for FFA, TG, total cholesterol, insulin and glucose were not significantly altered with chronic PI treatment (Fig. 1), with HOMA-IR also not showing any differences (data not shown, \(p>0.05\)). However, PI treatment increased serum LDL-cholesterol levels to 0.433±0.021 vs. 0.216±0.005 mM ( sham) \((p<0.05)\) and vs. 0.216±0.003 mM (vehicle) \((p<0.05)\). Furthermore, triglyceride content was significantly elevated in heart (Fig. 1G) and liver tissues (data not shown), while PI-treated hearts also exhibited higher HDL-cholesterol levels \((p<0.01)\ vs.
sham and vehicle) (Fig. 1H). No significant elevations were found for cardiac total cholesterol and VLDL-cholesterol content (p > 0.05) (Fig. 1 E, F). In addition, total food consumed in PI-treated animals was significantly higher than the control groups; i.e. 894 ± 17.8 g vs. 707 ± 14.3 g (sham) (p < 0.05) and vs. 717 ± 13.1 g (vehicle) (p < 0.05).

Figure 1. Serum and tissue lipid characterization (n = 8). A) serum FFA; B) serum LDL-cholesterol; C) serum TG; D) serum total cholesterol; E) cardiac total cholesterol; F) cardiac LDL-cholesterol; G) cardiac TG; and H) cardiac HDL-cholesterol. *p < 0.05, **p < 0.01 vs. sham; #p < 0.05, ##p < 0.01 vs. vehicle. Data presented as mean ± SEM and one-way ANOVA with Bonferroni post-hoc test performed for statistics. FFA – free fatty acids, HDL – high density lipoprotein, LDL – low density lipoprotein, PI – protease inhibitor, TG – triglyceride.

doi:10.1371/journal.pone.0073347.g001
Histological analysis (H & E staining) did not reveal major ultrastructural abnormalities for all tissues examined (Fig. 2A) while no fibrosis was detected (data not shown). To determine mechanisms responsible for early metabolic changes, we evaluated lipid and cholesterogenic genes in heart and liver tissues. Here PI treatment enhanced cardiac *gpam* expression (*p* < 0.001 vs. sham), although this was not significant vs. vehicle-treated rats (Fig. 2B). However, hepatic *accb* and *hmgcr* expression were significantly upregulated in the PI group (*p* < 0.05 vs. vehicle) (Fig. 2C). Since our gene data indicate PI-mediated transcriptional effects, we next assessed the expression of the transcriptional modulator SREBP-1. However, we found no significant alterations with PI treatment for nuclear (Fig. 2D) and cytosolic SREBP1 (data not shown).

Further analyses of heart function at baseline revealed significantly decreased contractile force with PI treatment. Here both maximal and minimal contractile forces were altered with 8 weeks of PI therapy (Table 1) when compared to both sham and vehicle-treated groups. No significant differences were found between the respective control groups.

We next evaluated the effects of PI treatment on the cardiac UPS system and our data demonstrate significantly lowered chymotrypsin-like and caspase-like, but not trypsin-like proteasomal activities (Fig. 3A). In parallel, global ubiquitination of total proteins significantly increased with PI administration (Fig. 3B). Since our earlier work pointed towards an alteration in SERCA-2a levels [17], we attempted to gain additional insight regarding PI-mediated contractile dysfunction, markers regulating this ion channel as well as a marker for electrical conductance. Here myocardial expression of the gap junction protein connexin 43 (marker for electrical conductance) and pPLB (SERCA-2a regulator) increased with PI treatment (Fig. 3C, D).

| Table 1. Effect of PIs on ex vivo heart function parameters at baseline (n = 8). |
|---|
| | Sham | Vehicle | PI |
| **+dP/dt (mmHg/sec)** | 1411.0 ± 126.9 | 1068.8 ± 70.9 | 633.1 ± 57.7 *** | ♯ |
| **−dP/dt (mmHg/sec)** | −966.8 ± 71.9 | −782.1 ± 118.2 | −338.4 ± 31.0 *** | ♯ |

Heart rate (bpm) 274.1 ± 10.6 283.5 ± 9.2 197.4 ± 36.0

Abbreviations: PI – protease inhibitor. ***p < 0.001 vs. sham; ♯p < 0.05 and ♯##p < 0.01 vs. vehicle. Data presented as mean ± SEM and two-way ANOVA with Bonferroni post-hoc test performed for statistics. No significant differences were found between the sham and vehicle groups, and statistical differences for PI are indicated with * or ♯ symbols.

doi:10.1371/journal.pone.0073347.t001

Since our earlier work pointed towards an alteration in SERCA-2a levels [17], we attempted to gain additional insight regarding PI-mediated contractile dysfunction, markers regulating this ion channel as well as a marker for electrical conductance. Here myocardial expression of the gap junction protein connexin 43 (marker for electrical conductance) and pPLB (SERCA-2a regulator) increased with PI treatment (Fig. 3C, D).
We next assessed calcium and mitochondrial energetic signaling markers and found that PIs significantly downregulated the expression of the calcium-binding protein calmodulin (Fig. 4A), while calcineurin was upregulated (Fig. 4B). However, pCaMKII levels remained unchanged while nuclear NFAT3 expression increased versus controls (p<0.05 vs. sham and vehicle) (Fig. 4C, D). Here expression of PGC-1α was significantly upregulated in PI-treated heart tissue (Fig. 5A) while no changes were found for mitochondrial biogenesis markers (NRF-1, mtTFA) (Fig. 5B, C).

Myocardial SOD activity within mitochondria was markedly upregulated (Fig. 6A, B) in PI-treated hearts. However, cardiac catalase activity and protein carbonylation did not differ for any of the experimental groups (Fig. 6C, D). The non-oxidative glucose pathways did not display any significant changes, except that PI treatment attenuated the AGE pathway, i.e. 6.25±0.52 vs. 14.87±2.05 nmol/mg protein (sham) (p<0.01) and vs. 13.16±2.23 nmol/mg protein (vehicle) (p>0.05) (Fig. 7).

Discussion

Although HAART markedly improves the quality of life and prognosis of HIV-infected individuals, it also elicits cardiometabolic side effects in the long-term. Since molecular mechanisms underlying this process are poorly understood, we evaluated early cardiometabolic changes in a rat model of PI treatment. The main findings of this study are: 1) PI-treated rats exhibited lipid abnormalities; and 2) Rats exposed to PIs display altered myocardial ubiquitin proteasome and calcium-handling pathways together with decreased contractile function.

**PI-treated rats exhibited lipid abnormalities.** Previous studies demonstrated that a significant proportion of HAART patients develops impaired glucose tolerance, IR (insulin resistance) and type 2 diabetes [11,12]. Here our data revealed that PI-treated rats displayed elevated serum LDL-cholesterol and cardiac/hepatic tissue triglyceride levels, identifying perturbed lipid metabolism as a relatively early occurrence. Although not focusing on initial PI-mediated changes, previous work also reported that lipid derangements are one of the commonest side-effects triggered by Lopinavir/Ritonavir usage [42]. Moreover, clinical studies indicate that altered fat partitioning (i.e. lipodystrophy) is common with PI treatment [7,43,44] compared to overt increases in weight gain, and that this occurs within the first year of therapy. Our data indicate that the onset of IR could follow at a later stage in the progression of cardio-metabolic dysfunction following PI treatment. In support, the HOMA-IR assessment and several non-oxidative pathways of glucose metabolism (HBP, PKC, polyol pathway), that are usually strongly linked to IR and type 2 diabetes, were not activated in our model. However, the AGE pathway was unexpectedly downregulated and further studies are required to elucidate whether this is a direct effect or if it occurs as a result of other changes triggered by PI treatment.

How exactly does PI treatment induce the changes in lipid metabolism here observed? The mechanisms underlying higher food consumption with PI exposure are unclear, but well-known regulators of dietary intake (e.g. leptin, neuropeptide Y, ghrelin) may be implicated [45] and therefore form part of our ongoing investigations. PI treatment induced gene expression of accb and hmgcr in the liver that would be expected to enhance fatty acid oxidation and cholesterol synthesis, respectively. There were also early signs of elevated cardiac gpm expression (although not statistically significant versus all matched controls), while it was robustly upregulated in adipose tissue (data not shown).
gene expression results therefore indicate that the higher serum LDL-cholesterol levels may result from greater adipose triglyceride synthesis and subsequent export to the liver and heart. Here increased hepatic 

Figure 4. Calcium pathway protein expression in response to chronic PI therapy (n = 6–8). A) Calmodulin; B) Calcineurin; C) pCaMKII; and D) NFAT3. *p<0.05, **p<0.01 vs. sham; #p<0.05, ###p<0.001 vs. vehicle. Data presented as mean ± SEM and one-way ANOVA with Bonferroni post-hoc test performed for statistics. NFAT3 – nuclear factor of activated T-cells 3, pCaMKII – phosphorylated CaMKII, PI – protease inhibitor.
doi:10.1371/journal.pone.0073347.g004

Figure 5. Myocardial peptide levels of transcriptional regulators of cardiac hypertrophy and mitochondrial biogenesis with 8 weeks PI therapy (n = 6–8). A) PGC-1α; B) NRF-1; and C) mtTFA. ***p<0.001 vs. sham; ###p<0.001 vs. vehicle. Data presented as mean ± SEM and one-way ANOVA with Bonferroni post-hoc test performed for statistics. NRF-1 nuclear respiratory factor 1, mtTFA – mitochondrial transcription factor A, PGC-1α – peroxisome proliferator-activated receptor gamma coactivator-1-alpha, PI – protease inhibitor.
doi:10.1371/journal.pone.0073347.g005
Figure 6. Myocardial oxidative stress profile (n = 8). A) Mitochondrial SOD activity; B) Protein carbonylation; and C) Myocardial catalase activity. ***p < 0.001 vs. sham; ###p < 0.001 vs. vehicle. Data presented as mean ± SEM and one-way ANOVA with Bonferroni post-hoc test performed for statistics. PI – protease inhibitor, SOD – superoxide dismutase.
doi:10.1371/journal.pone.0073347.g006

Figure 7. Profile of cardiac non-oxidative metabolic pathways (n = 8). A) AGE; B) PKC; C) Polyol pathway (D-sorbitol); D) HBP (O-GlcNAcylation); and E) Pentose phosphate pathway (transketolase). *p < 0.05 vs. sham; #p < 0.05 vs. vehicle. Data presented as mean ± SEM and one-way ANOVA with Bonferroni post-hoc test performed for statistics. AGE – advanced glycation end-products, HBP – hexosamine biosynthetic pathway, PI – protease inhibitor, PKC – protein kinase C.
doi:10.1371/journal.pone.0073347.g007
Since PIs may also have direct transcriptional effects that trigger gene expression, we also assessed whether SREBFs – well-known transcriptional regulators of several lipid and cholesterol synthesis genes [23] – are implicated in the observed gene induction. We found no significant differences when analyzing SREBP expression (gene and protein levels) in liver and heart tissues, and suggest that other transcriptional modulators that regulate lipid and cholesterol genes may be involved. An alternate explanation may relate to the fact that Ritonavir is a reversible and competitive inhibitor of specific 20S proteasome subunits [25]. Since the UPS also plays a key role to regulate SREBP-1 binding to target gene promoters (mediating its degradation) [27,28], lower UPS activity may lead to more SREBP-1 remaining bound to gene promoter(s). This in turn could result in greater induction of target genes, even though total SREBP expression levels were unaltered. These possibilities are currently being pursued in our laboratory.

Together our study shows that early changes induced by PI treatment resemble the metabolic syndrome, a combination of risk factors that predispose to the future onset of IR, type 2 diabetes and CVD. Moreover, the higher serum LDL-cholesterol levels mirror a pre-atherogenic state that may eventually trigger the onset of various cardiac complications, e.g. acute myocardial infarction.

Rats exposed to PIs display altered myocardial ubiquitin proteasome and calcium-handling pathways together with decreased contractile function

What are the underlying mechanisms whereby PI administration impairs contractile function? Our results show no significant remodeling of hearts exposed to PIs, i.e. lack of ultrastructural changes, fibrosis and cardiac hypertrophic response. We also evaluated markers for myocardial oxidative stress since others found a link between PI exposure and elevated ROS production [18–20], but found no evidence of damaging effects of myocardial oxidative stress at baseline (no changes in degree of protein carbonylation). However, PI-treated hearts exhibited augmented myocardial SOD activity suggesting that increased oxidative stress is blunted by intracellular defense systems. Thus, these data indicate that harmful effects of previously reported PI-induced ROS occur at a later stage during the HAART regimen. In agreement, there was no ROS-mediated induction of several non-oxidative glucose metabolic pathways in PI-treated rats. This contrasts our recent work where greater myocardial oxidative stress, HBP activation and apoptosis contributed to contractile dysfunction [35].

The heart functional data are consistent with our earlier work [17] and reveal attenuated contractile function without significant alterations to heart rate. Here the ±dP/dt findings implicate the myocardial calcium handling pathway, as diastolic calcium is a key determinant of contractile function and calcium signaling [46]. Since PI treatment decreased and increased myocardial UPS activity and ubiquitination, respectively, this may lead to an accumulation of contractile protein aggregates and impaired cardiac contractility and signaling pathways. For example, protein turnover of connexin 43, PLB and SERCA-2a are all regulated by the UPS [47–51] and may explain the higher expression levels found here and before by us [17]. Others have established that altered connexin 43 expression can precede arrhythmias, ventricular fibrillation and incorrect signal propagation in the long-term [52–57]. Therefore we tentatively suggest that elevated connexin 43 expression in our model may results in detrimental effects on contractile function in the future, especially within the context of HIV-AIDS.

We previously identified lower myocardial calcium levels and higher SERCA-2a protein expression with PI treatment [17], and now report attenuated and elevated calmodulin and pPLB expression levels, respectively. In parallel, we found increased myocardial calcineurin and NFAT3 expression levels. Of note, others found that cardiac-specific calcineurin overexpression resulted in enhanced pPLB and SERCA-2a expression and diminished phosphorylation and redistribution of connexin 43 [50]. This was associated with depressed contractility and cardiac hypertrophy. Here the authors proposed that connexin 43 may be a downstream target of calcineurin and that attenuated connexin 43 levels may be linked to perturbed gap junction assembly and arrhythmogenesis [50]. We propose that a similar scenario may exist in our model and that greater calcineurin activation is linked to elevated connexin 43 expression that may compromise gap junction function. Increased SERCA-2a, connexin 43 and pPLB expression may occur as a result of lower myocardial UPS and have also been implicated as downstream transcriptional targets of calcineurin [50]. Thus, elevated connexin 43 and pPLB expression may represent an adaptive response by PI-treated hearts to improve calcium handling, which may improve cardiac function. Higher calcineurin activation also leads to increased dephosphorylation and translocation of NFAT3 to the nucleus for activation of downstream targets, e.g. PGC-1α and pro-hypertrophic genes [59,60]. However, since the calcineurin-NFAT3 pathway did not result in cardiac hypertrophy in our model, we are of the opinion that longer-term activation may eventually result in a hypertrophic response. These findings, however, represent a model of altered cardiac physiology and suggest a potential association with PI-induced molecular alterations to key junction and ionic proteins that may precede the onset of contractile dysfunction. Moreover, the metabolic side-effects elicited by PI treatment in our model – although at a relatively early stage – may also affect heart function as a downstream target. Thus we do not imply that the protein expression alterations are directly associated with the altered contractility found in our model. Data linking these phenomena are scarce and therefore makes definitive conclusions difficult. Together these findings indicate that perturbed calcium handling may contribute to the PI-mediated contractile dysfunction found in our experimental model in the longer term. However, further studies are required to confirm whether this is indeed the case.

Since myocardial PGC-1α was upregulated, this implies that PIs exert initial effects at the mitochondrial level. PGC-1α is a well-described transcriptional regulator of mitochondrial biogenesis [61,62] and we propose that higher expression levels may represent an early compensatory response to energetic stress. In agreement with this notion, NRF-1 and mtTFA expression remained unaltered while we previously identified no changes for myocardial ATP levels and AMPKα expression following 8 weeks of PI administration [17]. It is likely that reduced UPS activity in PI-treated hearts may contribute to the increased PGC-1α levels here observed. In support, others established that lower UPS-mediated protein turnover in fibroblasts resulted in PGC-1α stabilization and mitochondrial biogenesis [63], while it can also be rapidly degraded in the nucleus [64]. The reason(s) as to why NRF-1 and mtTFA were not upregulated in response to PGC-1α remains unclear but could be a unique phenomenon within this animal model. Therefore we cautiously interpret our findings and conclude a potential association between proteasomal inhibition via PIs and activation of the PGC-1α pathway.
Cardio-Metabolic Effects of HIV-Pis

Study limitations
The data here generated do not allow us to make a direct causal link between metabolic/molecular alterations and decreased heart function with PI treatment. We propose that additional studies that investigate more markers of electrical conductance, ion homeostasis and mitochondrial biogenesis would be useful to help answer these questions. Further, transgenic mouse studies to generate gene knockout/knockdown of molecular targets here identified, together with PI exposure should further advance our understanding of PI-mediated cardio-metabolic complications.

In conclusion, our study demonstrates that early changes triggered by PI treatment include increased serum LDL-cholesterol and myocardial triglyceride levels, together with decreased cardiac function. Furthermore, PI exposure inhibits the myocardial UPS and leads to elevated calcineurin and connexin 43 expression that may contribute to cardiac contractile dysfunction in the long-term. Our findings also highlights potential molecular targets that may have detrimental metabolic and contractile effects. Thus our study alerts to the association between PI treatment and cardio-metabolic side effects and we propose that further clinical studies are needed to evaluate these pathways in HIV+ patients on chronic HAART.

Acknowledgments
This work was supported by the South African National Research Foundation and Stellenbosch University (MFE), the Conseil Régional de La Réunion and l’Europethe Jefferson (EB), and Pilot Fellowship in Academic Medicine (MSW).

Author Contributions
Conceived and designed the experiments: KMSER MFE. Performed the experiments: KMSER TLF MSW EB MFE. Contributed reagents/materials/analysis tools: MSW EB MFE. Wrote the paper: KMSER MFE.

References
1. World Health Organization (2011) Global HIV/AIDS response. Epidemiologic update and health sector progress towards Universal Access. Progress Report 2011.
2. Armstrong W, Calabrese I, Taege A (2005) HIV update 2005: Origins, issues, Prospects, and Complications. Clev Clin J Med 72: 73–78.
3. Melekhin VV, Shepherd BE, Sinnette SE, Rebeiro PF, Barkanie G, et al. (2009) Antiretroviral therapy initiation before, during, or after pregnancy in HIV-1-infected women: maternal virologic, immunologic, and clinical response. PLoS One 4: e6961.
4. Palella F (1998) Human immunodeficiency virus infection. N Engl J Med 339: 588–600.
5. Panther LA (2002) How HIV infection and its treatment affects the cardiovascular system: what is known, what is needed. Am J Physiol – Heart Circ Physiol 283: H1–H4.
6. Carr A, Samaras K, Chisholm DJ, Cooper DA (1998) Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 353: 1881–1883.
7. Carr A, Samaras K, Burton S, Law M, Freund J, et al. (1998) A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51–F58.
8. Hui DY (2003) Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 42: 81–92.
9. Grimpound SK, Grunfeld C, Kodler DP, Currier JS, Kraegen E, et al. (2002) State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 113: 210–210.
10. Carr A, Samaras K, Thorsdottir A, Kaufmann G, Chisholm D, et al. (1999) Diagnosis, prediction, and natural course of HIV-1-protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: a cohort study. Lancet 353: 2093–2099.
11. Gan S, Samaras K, Burton S, Law M, Freund J, et al. (2002) Altered Myocellular and Abdominal Fat partitioning Predict Disturbance in Insulin Action in HIV-Protease Inhibitor-related Lipodystrophy. Diabetes 51: 3163–3169.
12. Rudich A, Ben-Romano R, Erzon S, Bashan A (2005) Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors. Acta Physiol Scand 183: 75–88.
13. Friis-Moller N, Reiss P, Sabban CA, Weber R, Monforte AD, et al. (2007) Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356: 1723–1733.
14. Mundy KE, Goedtjener J, Overton ET, Henry K, Bush T, et al. (2011) High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy. Clin Infec Dis 52: 378–386.
15. Becker A, Silvia K, Stewart S, Lübbeke F, Eesop A, et al. (2010) Acute Coronary Syndromes in Treatment- Naíve Black South Africans with Human Immunodeficiency Virus Infection. J Interven Cardiol 23: 70–77.
16. Lekakia J, Tsiodras S, Romondos I, Palios J, Poualakos G, et al. (2008) HIV-positive patients treated with protease inhibitors have vascular changes resembling those observed in atherosclerotic cardiovascular disease. Clin Science 115: 189–196.
17. Reynders K, Eesop M (2013) The maladaptive effects of HIV protease inhibitors (Lopinavir/Ritonavir) on the rat heart. Int J Cardiol In press.
18. Macho A, Castedo M, Marchetti P, Aguilar JJ, Decaudin D, et al. (1995) Mitochondrial dysfunctions in circulating T lymphocytes from human immunodeficiency virus-1 carriers. Blood 86: 2481–2487.
19. Greenspan HC, Aruma OI (1994) Oxidative stress and apoptosis in HIV infection: a role for plant-derived metabolites with synergistic antioxidant activity. Immunol Today 15: 209–213.
20. Jiang B, Hebert VY, Li Y, Mathis JM, Alexander JS, et al. (2007) HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis. Toxicol Appl Pharmacol 224: 60–71.
21. Matarrese P, Gambardella L, Cassone A, Vella S, Cauda R, et al. (2003) Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors. J Immunol 170: 6006–6015.
22. Riddle TM, Kahel DG, Woollett LA, Fichtenbaum CJ, Hui DY (2000) HIV protease inhibitor induces fatty acid and steroid biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 275: 37514–37519.
23. Elecler D, Hugery B, Bosard P, Ferré P, Foulle F (2004) SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 86: 839–848. doi:10.1016/j.bioch.2004.09.018.
24. Vallette SM, Sanchez HB, Rosenfeld JM, Osborne TF, Biol TFJ, et al. (1996) A Direct Role for Sterol Regulatory Element Binding Protein in Activation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Gene. J Biol Chem 271: 12247–12253.
25. Schmidtke J, Holzshutter H, Bogo M, Kairies N, Groll M, et al. (1999) How an inhibitor of the HIV-1 protease modulates proteasome activity. J Biol Chem 274: 35734–35740.
26. Liang J, Dier R, Cooper D, Jamul H, Debecken R, et al. (2001) HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 7: 1327–1331.
27. Punja T, Bengoechea-Alonso MT, Ericsson J (2006) Phosphorylation and ubiquitination of the transcription factor sterol regulatory element-binding protein-1 in response to DNA binding. J Biol Chem 281: 25270–25286.
28. Hizano Y, Yoshida M, Shimizu M, Sato K (2001) Direct demonstration of rapid degradation of nuclear sterol regulatory element-binding proteins by the ubiquitin-proteasome pathway. J Biol Chem 276: 36431–36437.
29. Darley-Umap VM, Ball LE, Chatham JC (2012) Protein O-linked β-N-acetylglucosamine: a novel effector of cardiomycose metabolism and function. J Mol Cell Cardiol 52: 538–549.
30. Casco J, Sevilla J, De Castro J, Herrera E, Ramos MP (2008) Validation of simple indexes to assess insulin sensitivity during pregnancy in Wistar and Sprague-Dawley rats. Am J Physiol – Endocrinol Metab 295: E1269–E1276.
31. Willis MS, Schneider JC, Li K, de la Fuente-Garcia JI, Hilliard EG, et al. (2009) Cardiac muscle ring finger-1 increases susceptibility to heart failure in vivo. Circ Res 105: 80–88.
32. Willis MS, Ike C, Li L, Wang D-Z, Glass DJ, et al. (2007) Muscle ring finger 1, but not muscle ring finger 2, regulates cardiac hypertrophy in vivo. Circ Res 100: 456–459.
33. Andersen CL, Jensen JL, Orntoft TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64: 5245–5250.
34. Vandesompele J, De Preter K, Pattyn F, Poppe B, VanRoy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: research0034.1–research0034.11.
49. Laing JG, Beyer EC (1995) The gap junction protein connexin43 is degraded via the ubiquitin-proteasome pathway. J Biol Chem 270: 26399–26405.

48. VanSlyke JK, Musil LS (2002) Dislocation and degradation from the ER are regulated by cytosolic stress. J Cell Biol 157: 301–314.

47. VanSlyke JK, Deschenes SM, Musil LS (2000) Intracellular Transport, Assembly, and Degradation of Wild-Type and Disease-linked Mutant Gap Junction Proteins. Mol Biol Cell 11: 1933–1946.

46. Hecker PA, Mapanga RF, Kimar CP, Ribeiro RF, Brown BH, et al. (2012) Effects of glucose-6-phosphate dehydrogenase deficiency on the metabolic and cardiac responses to obesogenic or high-fructose diets. Am. J Physiol - Endocrin Metab 303: E959–E972.

45. Lagathu C, Kim M, Arribas J, Beall G, et al. (2002) Ritonavir versus neflinavir for the initial treatment of HIV infection. N Engl J Med 346: 2039–2046.

44. Ferrer E, Del Rio L, Martinez E, Curto J, Domingo P, et al. (2011) Impact of switching from Lopinavir/Ritonavir to Atazanavir/Ritonavir on body fat redistribution in virologically suppressed HIV-infected adults. AIDS 22: 2313–2321.

43. Carr A, Ritzerhaupt A, Zhang W, Zaidenverg R, Workman C, et al. (2008) Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocyte function in antiretroviral-naive adults. AIDS 22: 2313–2321.

42. Walmsley S, Bernstein B, King M, Arribas J, Beall G, et al. (2002) Ritonavir versus neflinavir for the initial treatment of HIV infection. N Engl J Med 346: 2039–2046.

41. Haba G De, Leder IG, Racker E (1955) Crystalline transketolase from bakers’ yeast: isolation and properties. J Biol Chem 214: 409–426.